Market Overview

UPDATE: Citigroup Initiates Amarin at Buy on Vascepa Overhang Removal

Related AMRN
Amarin Moves Higher On Speculation Of Special Protocol Assessment
Stocks To Watch For June 26, 2014

Citigroup initiated coverage on Amarin (NASDAQ: AMRN) with a Buy rating and a $20 price target.

Citigroup commented, "The overhang from the delayed 3 vs. 5 year FDA market exclusivity decision for AMRN's cardiovascular drug, Vascepa, has pressured the company's valuation towards our view of a near “worst case” scenario. We believe the current risk/reward is favorable, viewing Vascepa to have >$1B commercial potential even if AMRN were to “go alone” and further upside if a large pharma partner ultimately became involved. We believe 5 yr exclusivity for Vascepa is on the table, and a strategic transaction is feasible even if not granted. The FDA's delay will likely force AMRN to begin building a sales force and this increases chances of requiring additional capital to do so."

Amarin closed at $11.49 on Monday.

Posted-In: CitigroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters